Anti-cholesterol drug treats Alzheimer's disease in mice

ficant cognitive benefit for AD patients with normal serum cholesterol."

Although CP-113,818 has not been tested in clinical trials, another ACAT inhibitor, avasimibe, developed by Pfizer, is now in final clinical trials as a treatment for vascular disease and atherosclerosis. That drug is "considered safe for human use, with a good therapeutic window," wrote Kovacs and her colleagues.

"Our results suggest that slow-release biopolymer administration of ACAT inhibitors may be considered as a potential strategy for the treatment and prevention of Alzheimer's disease, alone or in combination with statins," they wrote.

Birgit Hutter-Paier, Henri J. Huttunen, Luigi Puglielli, Christopher B. Eckman, Doo Yeon Kim, Alexander Hofmeister, Robert D. Moir, Sarah B. Domnitz, Matthew P. Frosch, Manfred Windisch, and Dora M. Kovacs: "The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease"


Contact: Heidi Hardman
Cell Press

Page: 1 2

Related biology news :

1. Stem cell procedure successfully treats amyloidosis patients
2. New compound effectively treats fungal infections
3. Antibiotic treats lymphoma of the eye
4. Gene therapy advance treats hemophilia in mouse models
5. Device creates electricity and treats wastewater
6. Antarctic ice shelf retreats happened before
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions

Post Your Comments:

(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/28/2015)... 28, 2015 Synaptics Inc. (NASDAQ: SYNA ... announced that Lenovo has selected Synaptics , Natural ... its latest smartphone, the Vibe P1. The new ... the device and provide swift access to applications and ... Natural ID FS4202 sensor solution utilizes AES256-bit encryption of ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
Breaking Biology News(10 mins):
(Date:10/8/2015)... October 8, 2015 http://www.GoldmanResearch.com ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... 7, 2015  ChromaDex Corp. (OTCQX: CDXC), an ... that creates science-based solutions for dietary supplement, food ... products, today announced that the October 1 presentation ... is now available for on-demand viewing at VirtualInvestorConferences.com. ... http://tinyurl.com/101postpr   --> LINK: ...
Breaking Biology Technology:
Cached News: